Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexalin TechnologyNXL +0.18%38 Net Debt Paydown Yield % is 0% as of Aug. 20, 2026. GuruFocus rates NXL with a GF Score™ of 38/100 and a GF Value™ of $0.66 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 769 Medical Devices & Instruments companies, Nexalin Technology ranks worse than 130038.88% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Nexalin Technology's Net Debt Paydown Yield % was 0%.
Nexalin Technology (NAS:NXL) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Nexalin Technology Net Debt Paydown Yield % Related Terms
Nexalin Technology Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Nexalin Technology's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NXL vs ICCM, ADGM, ALRTF: Net Debt Paydown Yield % Comparison
For the Medical Devices subindustry, Nexalin Technology's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexalin Technology Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Nexalin Technology's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Nexalin Technology (NXL) has a Net Debt Paydown Yield % of 0% as of Aug. 20, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Nexalin Technology and its competitors. According to the industry distribution chart, Nexalin Technology ranks #999999 out of 769 companies in the Medical Devices & Instruments industry.
Is Nexalin Technology's Net Debt Paydown Yield % too high?
Nexalin Technology's current Net Debt Paydown Yield % is 0%. Based on the distribution chart, Nexalin Technology ranks #999999 out of 769 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nexalin Technology has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nexalin Technology's Net Debt Paydown Yield % compare to ICCM and ADGM?
According to the Medical Devices & Instruments industry distribution chart, Nexalin Technology ranks #999999 out of 769 companies for Net Debt Paydown Yield %. This places Nexalin Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
A good Net Debt Paydown Yield % depends on the Medical Devices & Instruments industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Nexalin Technology and its competitors. Nexalin Technology's current Net Debt Paydown Yield % is 0%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalin Technology stock overvalued right now?
Based on GuruFocus' analysis, Nexalin Technology (NXL) is currently considered Possible Value Trap. The stock's GF Value™ is $0.66, compared to a current price of $0.33 — trading 49.6% below its estimated fair value. The current Net Debt Paydown Yield % is 0%. Nexalin Technology's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Nexalin Technology (NXL), the current Net Debt Paydown Yield % is 0% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexalin Technology (NXL) Overvalued in 2026?
Based on GuruFocus' analysis, Nexalin Technology stock appears to be undervalued.
The current stock price of $0.33 is trading 49.6% below its estimated GF Value™ of $0.66.
GuruFocus considers Nexalin Technology to be Possible Value Trap.
Key valuation signals for NXL:
Net Debt Paydown Yield %: 0%
GF Value™: $0.66 vs. price of $0.33 (49.6% below fair value)
No single metric tells the full story. See the NXL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
38GF Score
Get the complete analysis for NXL
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXL has been successfully added to your 
